Quest Diagnostics Incorporated
Quest Diagnostics Incorporated (DGX) Financial Performance & Income Statement Overview
Explore the financials of Quest Diagnostics Incorporated (DGX), including yearly and quarterly data on income, cash flow, and balance sheets.
Quest Diagnostics Incorporated (DGX) Income Statement & Financial Overview
Analyze Quest Diagnostics Incorporated’s DGX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $2.65B | $2.62B | $2.49B | $2.40B |
| Cost of Revenue | $1.79B | $1.76B | $1.68B | $1.62B |
| Gross Profit | $863.00M | $858.00M | $811.00M | $776.00M |
| Gross Profit Ratio | $0.33 | $0.33 | $0.33 | $0.32 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $476.00M | $466.00M | $448.00M | $406.00M |
| Operating Expenses | $517.00M | $497.00M | $481.00M | $406.00M |
| Total Costs & Expenses | $2.31B | $2.26B | $2.16B | $2.03B |
| Interest Income | $5.00M | $7.00M | $9.00M | $3.00M |
| Interest Expense | $72.00M | $72.00M | $58.00M | $47.00M |
| Depreciation & Amortization | $140.00M | $135.00M | $125.00M | $117.00M |
| EBITDA | $488.00M | $507.00M | $479.00M | $478.00M |
| EBITDA Ratio | $0.18 | $0.19 | $0.19 | $0.20 |
| Operating Income | $346.00M | $361.00M | $330.00M | $370.00M |
| Operating Income Ratio | $0.13 | $0.14 | $0.13 | $0.15 |
| Other Income/Expenses (Net) | -$70.00M | -$62.00M | -$34.00M | -$41.00M |
| Income Before Tax | $276.00M | $299.00M | $296.00M | $314.00M |
| Income Before Tax Ratio | $0.10 | $0.11 | $0.12 | $0.13 |
| Income Tax Expense | $59.00M | $68.00M | $65.00M | $74.00M |
| Net Income | $220.00M | $222.00M | $226.00M | $229.00M |
| Net Income Ratio | $0.08 | $0.08 | $0.09 | $0.10 |
| EPS | $1.97 | $1.98 | $2.01 | $2.05 |
| Diluted EPS | $1.94 | $1.95 | $1.99 | $2.04 |
| Weighted Avg Shares Outstanding | $111.00M | $111.00M | $112.00M | $111.00M |
| Weighted Avg Shares Outstanding (Diluted) | $113.00M | $113.00M | $113.00M | $112.00M |
Financial performance has remained strong, with revenue growing from $2.40B in Q2 2024 to $2.65B in Q1 2025. Gross profit continued to perform well, with margins at 33% in the latest quarter. Operating income reached $346.00M in Q1 2025, holding a steady 13% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $488.00M. Net income dropped to $220.00M, keeping EPS at $1.97. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan